Adenosine Receptor A3 Market to be Lead Can-Fite BioPharma Ltd During Forecast Period of 2018-2022

Adenosine Receptor A3  

Overview

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardio protective function during cardiac ischemia.

It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3066581-adenosine-receptor-a3-adora3-pipeline-review-h1-2018

Top Companies mentioned

Can-Fite BioPharma Ltd

Adenosine Receptor A3 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Adenosine Receptor A3    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Adenosine Receptor A3   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 8, 4 and 1 respectively.

Adenosine Receptor A3 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Adenosine Receptor A3 - Competitive Analysis

Key players are making innovative developments in Adenosine Receptor A3 industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Adenosine Receptor A3.

The pipeline guide reviews pipeline therapeutics for Adenosine Receptor A3 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Adenosine Receptor A3 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Adenosine Receptor A3 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Adenosine Receptor A3.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3066581-adenosine-receptor-a3-adora3-pipeline-review-h1-2018

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.